Related Experiment Video
Updated: Jan 29, 2026

An Orthotopic Model of Serous Ovarian Cancer in Immunocompetent Mice for in vivo Tumor Imaging and Monitoring of Tumor Immune Responses
Published on: November 28, 2010
Normalizing the Tumor Microenvironment: A New Frontier in Ovarian Cancer Therapy
Adam P Jones1, Yanxia Zhao2, Bo R Rueda3
1Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
Abstract:
Ovarian cancer is one of the deadliest gynecological malignancies, where most patients become clinically symptomatic at advanced stages of disease due to the lack of effective diagnostic screening. Despite recent advances in surgical resection and chemotherapy, recurrent ovarian cancer remains largely refractory to treatment, resulting in poor prognosis. The ovarian cancer tumor microenvironment (TME) is highly abnormal and presents a significant barrier to successful therapy. A combination of abnormal vasculature, desmoplastic extracellular matrix, and aberrantly activated hypoxic and immune-suppressive pathways culminates in promoting tumor growth, dissemination, chemoresistance, and immunosuppression. Whilst immune checkpoint inhibitors have shown success in other cancers, their application in ovarian cancer, particularly at advanced stages, remains limited. In this review, we discussed the application of tumor extracellular matrix normalizing therapies in preclinical models of advanced ovarian cancer, and their synergistic benefit to chemotherapy and immunotherapy. Collectively, these insights underscore TME normalization as a promising therapeutic strategy with the potential to improve ovarian cancer management.
Insights
Tumor microenvironment (TME) normalization therapies show promise for treating advanced ovarian cancer. These approaches enhance chemotherapy and immunotherapy effectiveness, offering a new strategy for this deadly gynecological malignancy.
Area of Science:
- Oncology
- Gynecologic Oncology
- Cancer Immunology
Background:
- Ovarian cancer is a leading cause of gynecologic cancer death, often diagnosed at advanced stages.
- Recurrent ovarian cancer is difficult to treat due to resistance to chemotherapy and a complex tumor microenvironment (TME).
- The TME in ovarian cancer features abnormal vasculature, dense extracellular matrix, hypoxia, and immune suppression, hindering treatment efficacy.
Purpose of the Study:
- To review the application of tumor extracellular matrix normalizing therapies in preclinical models of advanced ovarian cancer.
- To evaluate the synergistic benefits of TME normalization with chemotherapy and immunotherapy.
- To highlight TME normalization as a potential therapeutic strategy for ovarian cancer.
Main Methods:
- Review of preclinical studies on tumor extracellular matrix normalizing therapies in advanced ovarian cancer models.
- Analysis of the impact of these therapies on chemotherapy and immunotherapy efficacy.
- Discussion of the role of TME normalization in overcoming treatment resistance and immunosuppression.
Main Results:
- Tumor extracellular matrix normalizing therapies demonstrate synergistic effects when combined with chemotherapy.
- These therapies enhance the efficacy of immunotherapy in preclinical ovarian cancer models.
- TME normalization strategies show potential to overcome treatment resistance and improve therapeutic outcomes.
Conclusions:
- Normalization of the tumor microenvironment is a promising therapeutic strategy for advanced ovarian cancer.
- Combining TME normalizing therapies with chemotherapy and immunotherapy could improve patient prognosis.
- Further research into TME normalization is warranted to translate these findings into clinical practice.
Related Concept Videos
The Tumor Microenvironment
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Normal Stress
When a rod is under axial loading, the internal forces and corresponding stress are normal to the plane of the section, so it is termed normal stress. It's important to...
Normal Distribution

